PRECLINICAL STUDY
Erythropoietin Enhances Neovascularization of Ischemic Myocardium and Improves Left Ventricular Dysfunction After Myocardial Infarction in Dogs
Akio Hirata, MD*,
Tetsuo Minamino, MD, PhD*,*,
Hiroshi Asanuma, MD, PhD*,
Masashi Fujita, MD*,
Masakatsu Wakeno, MD ,
Masafumi Myoishi, MD,
Osamu Tsukamoto, MD*,
Ken-ichiro Okada, MD*,
Hidekazu Koyama, BS*,
Kazuo Komamura, MD, PhD ,
Seiji Takashima, MD, PhD*,
Yoshiro Shinozaki, MD||,
Hidezo Mori, MD, PhD,
Masamichi Shiraga, MD, PhD ,
Masafumi Kitakaze, MD, PhD, FACC and
Masatsugu Hori, MD, PhD, FACC*
* Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine, Suita, Osaka, Japan
Department of Bioregulatory Medicine, Osaka University Graduate School of Medicine, Suita, Osaka, Japan
Department of Hematology and Oncology, Osaka University Graduate School of Medicine, Suita, Osaka, Japan
Cardiovascular Division of Internal Medicine, National Cardiovascular Center, Suita, Osaka, Japan
|| Department of Physiological Science, Tokai University School of Medicine, Isehara, Kanagawa, Japan.
Manuscript received June 14, 2005;
revised manuscript received November 10, 2005,
accepted November 30, 2005.
* Reprint requests and correspondence: Dr. Tetsuo Minamino, Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka 565-0871, Japan. (Email: minamino{at}medone.med.osaka-u.ac.jp).
OBJECTIVES: We investigated the effects of erythropoietin (EPO) on neovascularization and cardiac function after myocardial infarction (MI).
BACKGROUND: Erythropoietin exerts antiapoptotic effects and mobilizes endothelial progenitor cells (EPCs).
METHODS: We intravenously administered EPO (1,000 IU/kg) immediately [EPO(0) group], 6 h [EPO(6h) group], or 1 week [EPO(1wk) group] after the permanent ligation of the coronary artery in dogs. Control animals received saline immediately after the ligation.
RESULTS: The infarct size 6 h after MI was significantly smaller in the EPO(0) group than in the control group (61.5 ± 6.0% vs. 22.9 ± 2.2%). One week after MI, the circulating CD34-positive mononuclear cell numbers in both the EPO(0) and the EPO(6h) groups were significantly higher than in the control group. In the ischemic region, the capillary density and myocardial blood flow 4 weeks after MI was significantly higher in both the EPO(0) and the EPO(6h) groups than in the control group. Four weeks after MI, left ventricular (LV) ejection fraction in the EPO(6h) (48.6 ± 1.9%) group was significantly higher than that in either the control (41.9 ± 0.9%) or the EPO(1wk) (42.6 ± 1.2%) group but significantly lower than that in the EPO(0) group (56.1 ± 2.3%). The LV end-diastolic pressure 4 weeks after MI in both the EPO(0) and the EPO(6h) groups was significantly lower than either the control or the EPO(1wk) group. Hematologic parameters did not differ among the groups.
CONCLUSIONS: In addition to its acute infarct size-limiting effect, EPO enhances neovascularization, likely via EPC mobilization, and improves cardiac dysfunction in the chronic phase, although it has time-window limitations.
|
Abbreviations and Acronyms
| | ABP = arterial mean blood pressure | | Dil-ac-LDL = 1,1'-dioctadecyl-3,3,3',3'-tetramethylindocarbocyanine-labeled acetylated low density lipoprotein | | EPC = endothelial progenitor cell | | EPO = erythropoietin | | HR = heart rate | | LAD = left anterior descending coronary artery | | LCX = left circumflex coronary artery | | LV = left ventricle/ventricular | | LVEDD = left ventricular end-diastolic dimension | | LVEDP = left ventricular end-diastolic pressure | | MBF = myocardial blood flow | | MI = myocardial infarction | | MNC = mononuclear cell | | UEA-I = Ulex europaeus agglutinin I | | VEGF = vascular endothelial growth factor |
|
Related Article
-
Erythropoietin: Repair of the Failing Heart
- Peter van der Meer and Erik Lipsic
J. Am. Coll. Cardiol. 2006 48: 185-186.
[Full Text]
[PDF]
This article has been cited by other articles:
|
|
|
|
 
T. Yada, H. Shimokawa, O. Hiramatsu, M. Satoh, N. Kashihara, A. Takaki, M. Goto, Y. Ogasawara, and F. Kajiya
Erythropoietin enhances hydrogen peroxide-mediated dilatation of canine coronary collateral arterioles during myocardial ischemia in dogs in vivo
Am J Physiol Heart Circ Physiol,
December 1, 2010;
299(6):
H1928 - H1935.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. A. Voors, A. M. S. Belonje, F. Zijlstra, H. L. Hillege, S. D. Anker, R. H. J. A. Slart, R. A. Tio, A. van 't Hof, J. W. Jukema, H. O. J. Peels, et al.
A single dose of erythropoietin in ST-elevation myocardial infarction
Eur. Heart J.,
November 1, 2010;
31(21):
2593 - 2600.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Hamid and S. D. Prabhu
Erythropoietin and ventricular remodelling: a VEGF-dependent neovascularity
Cardiovasc Res,
July 1, 2010;
87(1):
6 - 7.
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. E. Burger, F.-L. Xiang, L. Hammoud, D. L. Jones, and Q. Feng
Erythropoietin Protects the Heart from Ventricular Arrhythmia during Ischemia and Reperfusion via Neuronal Nitric-Oxide Synthase
J. Pharmacol. Exp. Ther.,
June 1, 2009;
329(3):
900 - 907.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Rastogi, M. Imai, V. G. Sharov, S. Mishra, and H. N. Sabbah
Darbepoetin-{alpha} prevents progressive left ventricular dysfunction and remodeling in nonanemic dogs with heart failure
Am J Physiol Heart Circ Physiol,
December 1, 2008;
295(6):
H2475 - H2482.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D Mocini, P Muso, E Guendouz, L De Marco, L Mele, R Cini, P Sordini, A Alois, A Costantino, S Arima, et al.
Endogenous erythropoietin and a single bolus of 40,000 IU of epoetin alpha do not protect the heart from ischaemia-reperfusion injury during extracorporeal circulation for cardiac surgery
Perfusion,
May 1, 2008;
23(3):
187 - 192.
[Abstract]
[PDF]
|
|
|
|
|
|
|
E. Lipsic, B. D. Westenbrink, P. van der Meer, P. van der Harst, A. A. Voors, D. J. van Veldhuisen, R. G. Schoemaker, and W. H. van Gilst
Low-dose erythropoietin improves cardiac function in experimental heart failure without increasing haematocrit
Eur J Heart Fail,
January 1, 2008;
10(1):
22 - 29.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. D. Westenbrink, E. Lipsic, P. van der Meer, P. van der Harst, H. Oeseburg, G. J. Du Marchie Sarvaas, J. Koster, A. A. Voors, D. J. van Veldhuisen, W. H. van Gilst, et al.
Erythropoietin improves cardiac function through endothelial progenitor cell and vascular endothelial growth factor mediated neovascularization
Eur. Heart J.,
August 2, 2007;
28(16):
2018 - 2027.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Stamm
ICVTS on-line discussion B Don't give up, yet!
Interact CardioVasc Thorac Surg,
June 1, 2007;
6(3):
297 - 297.
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Asaumi, Y. Kagaya, M. Takeda, N. Yamaguchi, H. Tada, K. Ito, J. Ohta, T. Shiroto, K. Shirato, N. Minegishi, et al.
Protective Role of Endogenous Erythropoietin System in Nonhematopoietic Cells Against Pressure Overload-Induced Left Ventricular Dysfunction in Mice
Circulation,
April 17, 2007;
115(15):
2022 - 2032.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. van der Meer and E. Lipsic
Erythropoietin: Repair of the Failing Heart
J. Am. Coll. Cardiol.,
July 4, 2006;
48(1):
185 - 186.
[Full Text]
[PDF]
|
|
|
|
